Dose-escalated radiation therapy with and without short-course androgen deprivation for intermediate-risk prostate cancer - Abstract

AIM: To investigate outcomes in intermediate-risk (IR) prostate cancer patients receiving dose-escalated external beam radiation therapy (RT) with or without short-course androgen deprivation (ADT).

PATIENTS AND METHODS: This study comprised of 203 patients with IR prostate cancer who were treated at a single institution to a dose of 7,560 cGy or more between 2003-2010. Of these, 62 (30.5%) patients received ADT. Biochemical recurrence, distant metastatic-free survival, prostate cancer-specific survival, and overall survival were analyzed using the Kaplan-Meier method.

RESULTS: The median follow-up was 62 months and the median duration of ADT was 6 months. The 6-year biochemical control was 89.2% for those receiving RT plus ADT versus 76.7% in those receiving RT alone (p=0.02). There were no differences between the two groups regarding distant metastatic-free survival, prostate cancer-specific survival, and overall survival (respective p-values of 0.91, 0.50, 0.67).

CONCLUSION: Dose-escalated RT and short-course ADT results in improved biochemical outcomes for IR prostate cancer.

Written by:
Schreiber D, Rineer J, Surapaneni A, Navo E, Agarwal M, Nwokedi E, Rotman M, Schwartz D.   Are you the author?
Department of Veterans Affairs, New York Harbor Healthcare System, Brooklyn, New York, NY, U.S.A.; Department of Radiation Oncology, SUNY Downstate Medical Center, Brooklyn, NY, U.S.A; Department of Radiation Oncology, UF Orlando Health Center, Orlando, FL, U.S.A.  

Reference: Anticancer Res. 2014 Aug;34(8):4189-93.

PubMed Abstract
PMID: 25075045 Prostate Cancer Section







Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.